BiQ: BiQAP Update for 10/30/26

Action

Friday after the close, the FDA granted accelerated approval to INOVIO's VOCERYQ (INO-3107) for adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is no longer the only approved RRP therapy, and the market didn't wait for Monday to reprice PGEN shares. PGEN, which closed at $6.94, fell roughly 24% after hours, while INO nearly quadrupled from about $0.60.

My initial take was that this was a market overreaction. After doing a thesis review, however, my more considered opinion is that PAPZIMEOS is still the better product, and I expect it to keep most of the US market. But PGEN was priced for an uncontested franchise, and that's no longer the setup. A second therapy gives payers leverage, every patient is treated once, and the remaining upside levers sit in 2027 and beyond. I see limited risk-adjusted upside, so I'm removing PGEN from the BiQ Active Portfolio (BiQAP).

PGEN was originally added to the BiQAP on March 8, 2025 at a price of $1.86. Today's closing price was $6.94, and it closed at $5.30 after hours.

Discussion

VOCERYQ was approved on its PDUFA date under the accelerated pathway. It's Inovio's (INO) first approved product and the first FDA-approved DNA medicine.

Honestly, the accelerated approval surprised me. The pathway generally requires a meaningful advantage over available therapy, and PAPZIMEOS has full approval with roughly double the response rate. The FDA had itself questioned whether VOCERYQ qualified, and the confirmatory trial still hasn’t been designed.

RRP-001 enrolled 32 adults with two or more surgeries in the prior year. In the efficacy population (three or more surgeries), 7 of 26 patients (27%; 95% CI 12–48%) needed no surgery over 12 months. VOCERYQ is a plasmid DNA medicine given by intramuscular injection with Inovio's CELLECTRA 5PSP device. Full commercial launch is expected in Q1 2027.

IMO, PAPZIMEOS has the stronger hand on nearly every measure that drives prescribing:

• A 51% complete response rate (18/35) vs VOCERYQ's 27%, in patients with similar entry criteria (three or more surgeries in the prior year). It's a cross-trial comparison, but the gap is wide.
• At ASCO 2026, 83% of complete responders remained in complete response at a median of 36 months, with some beyond four years.
• No confirmatory trial hanging over the label.
• More than a year's head start with the key RRP centers, a permanent J-code (J3404) since April 1, and roughly 315 million covered lives.
• The RRP Foundation's expert consensus (Laryngoscope, January 2026) recommends HPV-specific immunotherapy first-line and names PAPZIMEOS.

VOCERYQ's case is convenience and non-responders:

• PAPZIMEOS requires removing visible papilloma before doses 3 and 4. VOCERYQ needs only the initial debulking.
• PAPZIMEOS is stored at −60°C or colder and needs biosafety handling. That can be a real hurdle for community practices.
• About half of PAPZIMEOS patients don't reach a complete response, and VOCERYQ is now the only other approved option.

VOCERYQ's weaknesses, however, are also real:

• The confirmatory trial still needs FDA alignment, which Inovio targets for mid-2027.
• Treatment requires the CELLECTRA device, with precautions for patients with pacemakers, defibrillators, or metal implants.
• Inovio's Q2 10-Q flagged substantial doubt. It had about $37 million of cash at June 30, plus about $18 million raised in July, and is building its field force through a contract sales organization.

Drug pricing is the swing factor. If INO prices VOCERYQ at parity, I expect PAPZIMEOS to take 80–85% of US starts. The efficacy gap and full approval should win most severe patients and the major academic centers. VOCERYQ picks up patients who want to avoid surgery during dosing, practices that can't handle ultra-cold storage, and PAPZIMEOS non-responders.

Below parity, the risk to PAPZIMEOS is more from pricing, not market share. Payers already restrict PAPZIMEOS beyond its label: Cigna and FEP Blue exclude retreatment, and FEP Blue and BCBS Kansas require three or more surgeries in the prior 12 months. A cheaper option invites step edits for less severe patients and larger rebate demands. So far discounting has been modest (gross-to-net guided to high teens to low 20s %), but that cushion is at risk.

All of this plays out in a finite market. Each patient gets one course; the prevalent pool is roughly 27,000 US adults by the company's estimate (others are lower), and new cases run around 1,000 a year. Revenue should peak as the severe backlog is treated, then settle into an incidence-driven tail. VOCERYQ takes a share, even if it's a minor one, of this same pool.

EU approval and retreatment approval are two additional factors in play, but neither is likely to impact revenue before 2028.

Precigen filed its MAA in November 2025 with orphan designation, and a CHMP opinion could arrive between late 2026 and mid-2027; however, I expect the economics to be modest. European prices typically run well below US levels, reimbursement goes country by country through health technology assessments, and Precigen hasn't announced a commercial partner. An approval would be a plus, but it's a 2028 revenue story at best – and most likely a modest one.

Retreatment is the bigger lever. Payer policies so far cover one course, and FEP Blue allows one authorization per lifetime. A Phase 4 study (n=30) that includes a retreatment cohort reaches primary completion in December 2027. Separately, an NCI study of PAPZIMEOS plus bevacizumab in previously treated patients is about to start. If retreatment works and payers accept it, the addressable market expands meaningfully, and the revenue tail lengthens. But data doesn't arrive until 2028, and then payer policies take time to change. Also, because PAPZIMEOS responses are so durable, retreatment candidates will mostly be non-responders and late relapsers.

I currently assign no value to anything in the pipeline beyond PAPZIMEOS. PRGN-2009 (HPV16/18, with pembrolizumab) is the only asset that could matter, and it's still too early. No Phase 2 efficacy data have been reported. The oropharyngeal Phase 2 uses an immunologic primary endpoint, the cervical Phase 2 is single-arm with 24 patients, and the only randomized test (NCI's neoadjuvant study, n=70) reads out around 2028.

It's also a crowded field with many failures. HPV16/18 cancers already draw therapeutic vaccines (PDS0101, ISA101b), mRNA (BioNTech's BNT113), TCR-T and ADCs, mostly built on a checkpoint-inhibitor backbone. Therapeutic HPV vaccines have a long record of immune responses that never became clinical benefit. Inovio's own VGX-3100 never made it to market.

The AdenoVerse Platform Technology Designation (September 2026) should speed manufacturing and regulatory work, but it says nothing about efficacy. The UltraCAR-T programs are effectively dormant. Management has promised a PRGN-2009 update by year-end. If it shows real clinical activity, I would likely revisit the thesis.

PGEN reports Q3 on Wednesday, November 4, after the close, and the stock could move hard either way.

The case for a run: consensus of about $73 million (set before the approval) compares with $55.0 million in Q2. Short interest was about 46 million shares in mid-October, roughly 20% of the float. A clean beat with confident commentary on the competition could squeeze shorts.

The case against:

• Q3 is the first quarter at steady-state gross margin, guided to the high 80s to low 90s % after Q2's inventory-flattered ~95%.
• Hub enrollment has grown at a steady pace, not an accelerating one, so Q2's 146% sequential jump is unlikely to repeat.
• Management has been quiet since August. How it talks about VOCERYQ matters as much as the numbers.

Bottom line: I still believe PAPZIMEOS is the better drug, and I expect it to keep the lion's share of the US RRP market. The problem is the stock was priced for a monopoly, and investors will likely be more cautious until they have a better idea of VOCERYQ's market share. With VOCERYQ approved, payers have leverage, the patient pool is finite and treated once, and the remaining upside levers (EU, retreatment, the pipeline) sit in 2027–28 or later. IMO, that leaves limited upside from here.

Although I'm removing PGEN from the BiQAP, I may still continue to hold a portion of my personal shares for now, mainly to see how Inovio prices VOCERYQ and how Q3 lands. A strong quarter could produce a nice bounce, but that's a trade, not a thesis, and carries additional risk.

Please refer to the BiQAP Active Portfolio page for additional information.

Please note that the BiQ ACB includes shares and all open options positions, which are accounted for using a "worst case scenario" assumption, plus realized trading profits (and losses) around my core position.

Not a BiQ Premium member, or have a friend who may be interested? Try BiQ Premium for $50 per month, or $375 (25% off) for the first year.

Biotech iQ is 100% subscriber supported. If you find this information helpful, please spread the word. You can also follow me on X @ Biotech iQ (_Biotech_iQ).

Biotech iQ is not an investment professional, and nothing on this page or this website should be considered investment advice. Please consult with a licensed investment professional as necessary. Past performance is not indicative of future results.